比较在英格兰社区接受 sotrovimab 治疗的 BA.1 和 BA.2 COVID-19 病例住院风险。
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.
机构信息
UKHSA COVID-19 National Epidemiology Cell, London, UK.
UKHSA Genomics and Public Health Analysis, London, UK.
出版信息
Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150.
Abstract
There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.
摘要
人们担心索特罗维单抗降低了对奥密克戎 SARS-CoV-2 变异株 BA.2 亚谱系的住院风险的疗效。我们对在社区中接受索特罗维单抗治疗的个体进行了一项回顾性队列（n=8850）研究，目的是评估 BA.2 病例与 BA.1 相比，住院风险是否存在差异。我们估计住院时间为 2 天或以上的住院入院风险比为 1.17（95%CI 0.74-1.86）。这些结果表明，两种亚谱系之间的住院风险相似。
相似文献
1
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.比较在英格兰社区接受 sotrovimab 治疗的 BA.1 和 BA.2 COVID-19 病例住院风险。
Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150.
2
Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.奥密克戎 BA.2 感染患者中，索特罗维单抗预防 COVID-19 相关住院或死亡的真实世界疗效。
J Infect Public Health. 2024 Feb;17(2):315-320. doi: 10.1016/j.jiph.2023.11.029. Epub 2023 Dec 30.
3
Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.在英格兰，与奥密克戎变异株 BA.1 相比，SARS-COV-2 变异株 BA.2 亚谱系导致住院和死亡的风险。
Nat Commun. 2022 Oct 13;13(1):6053. doi: 10.1038/s41467-022-33740-9.
4
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.在英格兰国民保健服务体系（NHS）医院中，推测接受索托维单抗治疗的新冠病毒疾病（COVID-19）患者的特征及治疗结果
BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2.
5
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.在社区患者中比较 sotrovimab 和 molnupiravir 预防重症 COVID-19 结局的效果：利用 OpenSAFELY 平台开展的观察性队列研究。
BMJ. 2022 Nov 16;379:e071932. doi: 10.1136/bmj-2022-071932.
6
Real-world severe COVID-19 outcomes associated with use of antivirals and neutralising monoclonal antibodies in Scotland.苏格兰使用抗病毒药物和中和单克隆抗体与真实世界中严重 COVID-19 结局的相关性。
NPJ Prim Care Respir Med. 2024 Jun 28;34(1):17. doi: 10.1038/s41533-024-00374-x.
7
Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.比利时使用 sotrovimab 治疗以预防 COVID-19 进展为重症的患者的特征和结局。
Acta Clin Belg. 2024 Jun;79(3):174-183. doi: 10.1080/17843286.2024.2381272. Epub 2024 Jul 31.
8
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.奥密克戎 BA.2 亚变体流行期间索特罗维单抗治疗 SARS-CoV-2 感染的真实世界疗效：系统文献回顾。
Infection. 2024 Feb;52(1):1-17. doi: 10.1007/s15010-023-02098-5. Epub 2023 Sep 30.
9
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.中和抗体疗法索特罗维单抗治疗 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 亚变种感染患者的临床疗效。
Viruses. 2023 May 31;15(6):1300. doi: 10.3390/v15061300.
10
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.奥密克戎 BA.1 和 BA.1.1 亚型为主流行期间，索特罗维单抗对预防高风险 COVID-19 门诊患者住院和死亡的有效性变化。
Int J Infect Dis. 2023 Mar;128:310-317. doi: 10.1016/j.ijid.2022.10.002. Epub 2022 Oct 10.
引用本文的文献
1
Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia.索托维单抗在澳大利亚悉尼西部感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2患者中的真实世界有效性
J Med Virol. 2025 Feb;97(2):e70235. doi: 10.1002/jmv.70235.
2
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
3
COVID-19 therapeutics.新型冠状病毒治疗药物。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0011923. doi: 10.1128/cmr.00119-23. Epub 2024 May 21.
4
Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.在英格兰国民保健服务体系（NHS）医院中，推测接受索托维单抗治疗的新冠病毒疾病（COVID-19）患者的特征及治疗结果
BMC Infect Dis. 2024 Apr 22;24(1):428. doi: 10.1186/s12879-024-09311-2.
5
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.奥密克戎 BA.2 和 BA.5 亚型为主流行期间，索特罗维单抗治疗 SARS-CoV-2 感染的真实世界疗效：系统文献回顾。
Infection. 2024 Oct;52(5):1839-1861. doi: 10.1007/s15010-024-02245-6. Epub 2024 Apr 11.
6
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study.在伦敦西北部，非住院的高危 COVID-19 患者中，与不治疗相比，sotrovimab 的疗效比较：一项回顾性队列研究。
BMJ Open Respir Res. 2024 Apr 4;11(1):e002238. doi: 10.1136/bmjresp-2023-002238.
7
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).索托维单抗用于新冠早期治疗的真实世界有效性：来自美国国家新冠队列协作组（N3C）的证据
Clin Drug Investig. 2024 Mar;44(3):183-198. doi: 10.1007/s40261-024-01344-4. Epub 2024 Feb 20.
8
Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.评估索特罗维单抗治疗奥密克戎亚变体 BA.2 与 BA.1 的体内疗效：一项多中心、回顾性队列研究。
BMC Res Notes. 2024 Jan 24;17(1):37. doi: 10.1186/s13104-024-06695-x.
9
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.奥密克戎 BA.2 亚变体流行期间索特罗维单抗治疗 SARS-CoV-2 感染的真实世界疗效：系统文献回顾。
Infection. 2024 Feb;52(1):1-17. doi: 10.1007/s15010-023-02098-5. Epub 2023 Sep 30.
10
Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report.在使用奥妥珠单抗和苯达莫司汀治疗滤泡性淋巴瘤期间出现的新型冠状病毒2型（SARS-CoV-2）长期感染：一例报告
Clin Case Rep. 2023 Aug 28;11(9):e7861. doi: 10.1002/ccr3.7861. eCollection 2023 Sep.
本文引用的文献
1
Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.在英格兰，与奥密克戎变异株 BA.1 相比，SARS-COV-2 变异株 BA.2 亚谱系导致住院和死亡的风险。
Nat Commun. 2022 Oct 13;13(1):6053. doi: 10.1038/s41467-022-33740-9.
2
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).索托维单抗治疗轻至中度新冠病毒奥密克戎变异株感染的极高风险患者的结局：一项前瞻性队列研究（法国国家艾滋病研究机构0003S COCOPREV研究）
J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎（B.1.1.529）和德尔塔（B.1.617.2）变异株的关系：一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
5
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
6
Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England.英格兰基于实验室的 COVID-19 病例监测的及时性和完整性。
Public Health. 2021 May;194:163-166. doi: 10.1016/j.puhe.2021.03.012. Epub 2021 Apr 1.
Zotero 插件